MAbs . A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351

[tetano]

MAbs


. Jan-Dec 2021;13(1):1930636.
doi: 10.1080/19420862.2021.1930636.
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351


Chunyin Gu ¹ , Xiaodan Cao ¹ , Zongda Wang ¹ , Xue Hu ² , Yanfeng Yao ³ , Yiwu Zhou ⁴ , Peipei Liu ¹ , Xiaowu Liu ¹ , Ge Gao ³ , Xiao Hu ² , Yecheng Zhang ² , Zhen Chen ² , Li Gao ¹ , Yun Peng ³ , Fangfang Jia ¹ , Chao Shan ² , Li Yu ¹ , Kunpeng Liu ² , Nan Li ¹ , Weiwei Guo ² , Guoping Jiang ¹ , Juan Min ³ , Jianjian Zhang ¹ , Lu Yang ¹ , Meng Shi ¹ , Tianquan Hou ¹ , Yanan Li ¹ , Weichen Liang ¹ , Guoqiao Lu ¹ , Congyi Yang ¹ , Yuting Wang ¹ , Kaiwen Xia ¹ , Zheng Xiao ¹ , Jianhua Xue ¹ , Xueyi Huang ¹ , Xin Chen ¹ , Haixia Ma ³ , Donglin Song ³ , Zhongzong Pan ¹ , Xueping Wang ¹ , Haibing Guo ¹ , Hong Liang ¹ , Zhiming Yuan ³ , Wuxiang Guan ³ , Su-Jun Deng ¹



Affiliations

• PMID: 34097570
• DOI: 10.1080/19420862.2021.1930636

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.

Keywords: B.1.1.7; B.1.351; D614G; JMB2002; SARS-CoV-2; broad-spectrum; neutralizing antibody; phage-to-yeast; rhesus macaque disease model.